Illumina (ILMN) Competitors

$114.46
-0.55 (-0.48%)
(As of 05/16/2024 ET)

ILMN vs. WAT, BRKR, BIO, AVTR, RVTY, BIO.B, ALNY, BAX, LH, and COO

Should you be buying Illumina stock or one of its competitors? The main competitors of Illumina include Waters (WAT), Bruker (BRKR), Bio-Rad Laboratories (BIO), Avantor (AVTR), Revvity (RVTY), Bio-Rad Laboratories (BIO.B), Alnylam Pharmaceuticals (ALNY), Baxter International (BAX), Laboratory Co. of America (LH), and Cooper Companies (COO).

Illumina vs.

Waters (NYSE:WAT) and Illumina (NASDAQ:ILMN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

Waters presently has a consensus target price of $305.78, suggesting a potential downside of 15.17%. Illumina has a consensus target price of $164.65, suggesting a potential upside of 43.85%. Given Waters' stronger consensus rating and higher possible upside, analysts clearly believe Illumina is more favorable than Waters.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Waters
1 Sell rating(s)
9 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.90
Illumina
2 Sell rating(s)
10 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.30

Illumina received 650 more outperform votes than Waters when rated by MarketBeat users. Likewise, 65.71% of users gave Illumina an outperform vote while only 54.30% of users gave Waters an outperform vote.

CompanyUnderperformOutperform
WatersOutperform Votes
429
54.30%
Underperform Votes
361
45.70%
IlluminaOutperform Votes
1079
65.71%
Underperform Votes
563
34.29%

In the previous week, Waters had 42 more articles in the media than Illumina. MarketBeat recorded 60 mentions for Waters and 18 mentions for Illumina. Waters' average media sentiment score of 0.78 beat Illumina's score of 0.05 indicating that Illumina is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Waters
10 Very Positive mention(s)
2 Positive mention(s)
27 Neutral mention(s)
7 Negative mention(s)
8 Very Negative mention(s)
Neutral
Illumina
8 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Waters has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Illumina has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Waters has a net margin of 20.75% compared to Waters' net margin of -28.71%. Illumina's return on equity of 66.59% beat Waters' return on equity.

Company Net Margins Return on Equity Return on Assets
Waters20.75% 66.59% 14.96%
Illumina -28.71%2.31%1.31%

94.0% of Waters shares are owned by institutional investors. Comparatively, 89.4% of Illumina shares are owned by institutional investors. 0.8% of Waters shares are owned by company insiders. Comparatively, 0.2% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Waters has higher earnings, but lower revenue than Illumina. Illumina is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waters$2.96B7.23$642.23M$10.1935.37
Illumina$4.50B4.05-$1.16B-$8.15-14.04

Summary

Waters beats Illumina on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ILMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ILMN vs. The Competition

MetricIlluminaAnalytical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$18.23B$5.63B$5.11B$7.96B
Dividend YieldN/A0.39%37.02%3.93%
P/E Ratio-14.0432.92170.5718.78
Price / Sales4.055.172,310.3479.10
Price / Cash31.4742.3536.0031.19
Price / Book3.182.485.464.47
Net Income-$1.16B-$10.98M$105.07M$217.14M
7 Day Performance2.79%0.50%1.66%1.89%
1 Month Performance-2.74%2.70%3.87%5.33%
1 Year Performance-43.31%-22.19%7.88%11.56%

Illumina Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
WAT
Waters
3.4217 of 5 stars
$358.99
+2.8%
$305.78
-14.8%
+35.4%$21.30B$2.96B35.237,900Insider Selling
BRKR
Bruker
4.9303 of 5 stars
$75.67
+1.9%
$84.86
+12.1%
+3.2%$11.00B$2.96B27.529,707Positive News
BIO
Bio-Rad Laboratories
4.6509 of 5 stars
$294.05
+3.0%
$461.00
+56.8%
-23.1%$8.39B$2.67B-28.388,030Short Interest ↑
AVTR
Avantor
4.2192 of 5 stars
$25.12
+3.4%
$26.71
+6.4%
+25.0%$17.06B$6.87B64.4014,500Options Volume
Positive News
RVTY
Revvity
3.0106 of 5 stars
$106.53
+0.9%
$118.17
+10.9%
N/A$13.14B$2.75B88.0411,500Positive News
BIO.B
Bio-Rad Laboratories
0 of 5 stars
$279.91
flat
N/A-25.1%$7.98B$2.67B-27.027,900
ALNY
Alnylam Pharmaceuticals
4.457 of 5 stars
$147.89
-1.3%
$216.19
+46.2%
-20.8%$18.71B$1.83B-55.182,100Short Interest ↑
BAX
Baxter International
4.7878 of 5 stars
$35.23
-0.6%
$45.73
+29.8%
-18.2%$17.95B$14.81B6.7860,000
LH
Laboratory Co. of America
4.985 of 5 stars
$211.20
+0.4%
$243.14
+15.1%
-2.0%$17.80B$12.16B42.5067,000Insider Selling
Short Interest ↓
COO
Cooper Companies
3.6829 of 5 stars
$95.96
+3.4%
$109.48
+14.1%
+1.0%$19.07B$3.59B65.6115,000

Related Companies and Tools

This page (NASDAQ:ILMN) was last updated on 5/17/2024 by MarketBeat.com Staff

From Our Partners